These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. 1-Deoxy-d-xylulose 5-phosphate reductoisomerase as target for anti Toxoplasma gondii agents: crystal structure, biochemical characterization and biological evaluation of inhibitors. Mazzone F; Hoeppner A; Reiners J; Gertzen CGW; Applegate V; Abdullaziz MA; Gottstein J; Degrandi D; Wesemann M; Kurz T; Smits SHJ; Pfeffer K Biochem J; 2024 Aug; 481(16):1075-1096. PubMed ID: 39105673 [TBL] [Abstract][Full Text] [Related]
45. Immuno-antibiotics: targeting microbial metabolic pathways sensed by unconventional T cells. Eberl M; Oldfield E; Herrmann T Immunother Adv; 2021 Jan; 1(1):ltab005. PubMed ID: 35919736 [TBL] [Abstract][Full Text] [Related]
46. Apicoplast Journey and Its Essentiality as a Compartment for Malaria Parasite Survival. Saggu GS Front Cell Infect Microbiol; 2022; 12():881825. PubMed ID: 35463632 [No Abstract] [Full Text] [Related]
47. Potent, specific MEPicides for treatment of zoonotic staphylococci. Edwards RL; Heueck I; Lee SG; Shah IT; Miller JJ; Jezewski AJ; Mikati MO; Wang X; Brothers RC; Heidel KM; Osbourn DM; Burnham CD; Alvarez S; Fritz SA; Dowd CS; Jez JM; Odom John AR PLoS Pathog; 2020 Jun; 16(6):e1007806. PubMed ID: 32497104 [TBL] [Abstract][Full Text] [Related]
48. The Methylerythritol Phosphate Pathway: Promising Drug Targets in the Fight against Tuberculosis. Wang X; Dowd CS ACS Infect Dis; 2018 Mar; 4(3):278-290. PubMed ID: 29390176 [TBL] [Abstract][Full Text] [Related]
50. Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin. Guggisberg AM; Sundararaman SA; Lanaspa M; Moraleda C; González R; Mayor A; Cisteró P; Hutchinson D; Kremsner PG; Hahn BH; Bassat Q; Odom AR J Infect Dis; 2016 Oct; 214(7):1085-91. PubMed ID: 27443612 [TBL] [Abstract][Full Text] [Related]
51. FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity. Wiesner J; Ziemann C; Hintz M; Reichenberg A; Ortmann R; Schlitzer M; Fuhst R; Timmesfeld N; Vilcinskas A; Jomaa H Virulence; 2016 Aug; 7(6):718-28. PubMed ID: 27260413 [TBL] [Abstract][Full Text] [Related]
52. Imlay LS; Armstrong CM; Masters MC; Li T; Price KE; Edwards RL; Mann KM; Li LX; Stallings CL; Berry NG; O'Neill PM; Odom AR ACS Infect Dis; 2015 Apr; 1(4):157-167. PubMed ID: 26783558 [TBL] [Abstract][Full Text] [Related]
53. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr). Armstrong CM; Meyers DJ; Imlay LS; Freel Meyers C; Odom AR Antimicrob Agents Chemother; 2015 Sep; 59(9):5511-9. PubMed ID: 26124156 [TBL] [Abstract][Full Text] [Related]
54. Synthesis of functionalized cinnamaldehyde derivatives by an oxidative Heck reaction and their use as starting materials for preparation of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors. Nordqvist A; Björkelid C; Andaloussi M; Jansson AM; Mowbray SL; Karlén A; Larhed M J Org Chem; 2011 Nov; 76(21):8986-98. PubMed ID: 21936546 [TBL] [Abstract][Full Text] [Related]
55. Biochemistry of the non-mevalonate isoprenoid pathway. Gräwert T; Groll M; Rohdich F; Bacher A; Eisenreich W Cell Mol Life Sci; 2011 Dec; 68(23):3797-814. PubMed ID: 21744068 [TBL] [Abstract][Full Text] [Related]
56. Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways. Baumeister S; Wiesner J; Reichenberg A; Hintz M; Bietz S; Harb OS; Roos DS; Kordes M; Friesen J; Matuschewski K; Lingelbach K; Jomaa H; Seeber F PLoS One; 2011 May; 6(5):e19334. PubMed ID: 21573242 [TBL] [Abstract][Full Text] [Related]
57. Structure of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway. Rekittke I; Wiesner J; Röhrich R; Demmer U; Warkentin E; Xu W; Troschke K; Hintz M; No JH; Duin EC; Oldfield E; Jomaa H; Ermler U J Am Chem Soc; 2008 Dec; 130(51):17206-7. PubMed ID: 19035630 [TBL] [Abstract][Full Text] [Related]
58. From molecular fossils of bacterial hopanoids to the formation of isoprene units: discovery and elucidation of the methylerythritol phosphate pathway. Rohmer M Lipids; 2008 Dec; 43(12):1095-107. PubMed ID: 19011917 [TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Na-Bangchang K; Ruengweerayut R; Karbwang J; Chauemung A; Hutchinson D Malar J; 2007 May; 6():70. PubMed ID: 17531088 [TBL] [Abstract][Full Text] [Related]
60. Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Borrmann S; Lundgren I; Oyakhirome S; Impouma B; Matsiegui PB; Adegnika AA; Issifou S; Kun JF; Hutchinson D; Wiesner J; Jomaa H; Kremsner PG Antimicrob Agents Chemother; 2006 Aug; 50(8):2713-8. PubMed ID: 16870763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]